Annual CFO
-$247.06 M
+$10.66 M+4.14%
December 31, 2023
Summary
- As of February 21, 2025, ARQT annual cash flow from operations is -$247.06 million, with the most recent change of +$10.66 million (+4.14%) on December 31, 2023.
- During the last 3 years, ARQT annual CFO has fallen by -$134.02 million (-118.57%).
- ARQT annual CFO is now -6444.56% below its all-time high of -$3.77 million, reached on December 31, 2017.
Performance
ARQT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$34.69 M
+$10.43 M+23.12%
September 30, 2024
Summary
- As of February 21, 2025, ARQT quarterly cash flow from operations is -$34.69 million, with the most recent change of +$10.43 million (+23.12%) on September 30, 2024.
- Over the past year, ARQT quarterly CFO has increased by +$9.30 million (+21.13%).
- ARQT quarterly CFO is now -390.36% below its all-time high of -$7.07 million, reached on March 31, 2019.
Performance
ARQT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$167.65 M
+$9.30 M+5.25%
September 30, 2024
Summary
- As of February 21, 2025, ARQT TTM cash flow from operations is -$167.65 million, with the most recent change of +$9.30 million (+5.25%) on September 30, 2024.
- Over the past year, ARQT TTM CFO has increased by +$94.22 million (+35.98%).
- ARQT TTM CFO is now -2270.00% below its all-time high of -$7.07 million, reached on March 31, 2019.
Performance
ARQT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ARQT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.1% | +21.1% | +36.0% |
| 3 y3 years | -118.6% | +21.1% | +36.0% |
| 5 y5 years | -1654.0% | +21.1% | +36.0% |
ARQT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -41.5% | +4.1% | -9.8% | +56.8% | at high | +41.3% |
| 5 y | 5-year | -476.8% | +4.1% | -106.5% | +56.8% | -291.4% | +41.3% |
| alltime | all time | -6444.6% | +4.1% | -390.4% | +56.8% | -2270.0% | +41.3% |
Arcutis Biotherapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$34.69 M(-23.1%) | -$167.65 M(-5.3%) |
| Jun 2024 | - | -$45.12 M(+42.8%) | -$176.95 M(-10.8%) |
| Mar 2024 | - | -$31.60 M(-43.8%) | -$198.32 M(-19.7%) |
| Dec 2023 | -$247.06 M(-4.1%) | -$56.24 M(+27.9%) | -$247.06 M(-5.7%) |
| Sep 2023 | - | -$43.98 M(-33.8%) | -$261.88 M(-8.3%) |
| Jun 2023 | - | -$66.48 M(-17.2%) | -$285.59 M(+1.6%) |
| Mar 2023 | - | -$80.34 M(+13.1%) | -$281.08 M(+9.1%) |
| Dec 2022 | -$257.71 M(+47.6%) | -$71.06 M(+5.0%) | -$257.71 M(+8.1%) |
| Sep 2022 | - | -$67.69 M(+9.2%) | -$238.36 M(+12.7%) |
| Jun 2022 | - | -$61.98 M(+8.8%) | -$211.55 M(+14.1%) |
| Mar 2022 | - | -$56.98 M(+10.2%) | -$185.40 M(+6.2%) |
| Dec 2021 | -$174.63 M | -$51.71 M(+26.5%) | -$174.63 M(+12.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$40.88 M(+14.1%) | -$155.49 M(+4.9%) |
| Jun 2021 | - | -$35.83 M(-22.4%) | -$148.30 M(+7.3%) |
| Mar 2021 | - | -$46.20 M(+41.9%) | -$138.23 M(+22.3%) |
| Dec 2020 | -$113.03 M(+163.9%) | -$32.57 M(-3.3%) | -$113.03 M(+16.2%) |
| Sep 2020 | - | -$33.69 M(+30.8%) | -$97.26 M(+30.9%) |
| Jun 2020 | - | -$25.76 M(+22.6%) | -$74.29 M(+30.9%) |
| Mar 2020 | - | -$21.01 M(+25.1%) | -$56.77 M(+32.5%) |
| Dec 2019 | -$42.84 M(+204.1%) | -$16.80 M(+56.7%) | -$42.84 M(+64.5%) |
| Sep 2019 | - | -$10.72 M(+30.1%) | -$26.04 M(+70.0%) |
| Jun 2019 | - | -$8.24 M(+16.5%) | -$15.32 M(+116.5%) |
| Mar 2019 | - | -$7.07 M | -$7.07 M |
| Dec 2018 | -$14.09 M(+273.1%) | - | - |
| Dec 2017 | -$3.77 M | - | - |
FAQ
- What is Arcutis Biotherapeutics annual cash flow from operations?
- What is the all time high annual CFO for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics annual CFO year-on-year change?
- What is Arcutis Biotherapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics quarterly CFO year-on-year change?
- What is Arcutis Biotherapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics TTM CFO year-on-year change?
What is Arcutis Biotherapeutics annual cash flow from operations?
The current annual CFO of ARQT is -$247.06 M
What is the all time high annual CFO for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high annual cash flow from operations is -$3.77 M
What is Arcutis Biotherapeutics annual CFO year-on-year change?
Over the past year, ARQT annual cash flow from operations has changed by +$10.66 M (+4.14%)
What is Arcutis Biotherapeutics quarterly cash flow from operations?
The current quarterly CFO of ARQT is -$34.69 M
What is the all time high quarterly CFO for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high quarterly cash flow from operations is -$7.07 M
What is Arcutis Biotherapeutics quarterly CFO year-on-year change?
Over the past year, ARQT quarterly cash flow from operations has changed by +$9.30 M (+21.13%)
What is Arcutis Biotherapeutics TTM cash flow from operations?
The current TTM CFO of ARQT is -$167.65 M
What is the all time high TTM CFO for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high TTM cash flow from operations is -$7.07 M
What is Arcutis Biotherapeutics TTM CFO year-on-year change?
Over the past year, ARQT TTM cash flow from operations has changed by +$94.22 M (+35.98%)